Daewoong Pharmaceutical's 'Nabota' Approved in Australia... Authorized in 61 Countries Worldwide

Daewoong Pharmaceutical's botulinum toxin 'Nabota' (exported to Australia under the name Nuceiva)
[Photo by Daewoong Pharmaceutical]

[Asia Economy Reporter Chunhee Lee] Daewoong Pharmaceutical announced on the 25th that its botulinum toxin (BTX) product, Nabota (export name Nuciva), recently obtained product approval in Australia. With this Australian approval, Nabota has been authorized in 61 countries worldwide. The company aims to secure approvals in more than 100 countries in the future.

The approved product is Nuciva 100 units. It took about a year since partner company Evolus applied for approval to the Australian Therapeutic Goods Administration (TGA) in December 2021 to obtain the approval. The launch is scheduled for the second half of this year or the first half of next year.

Evolus, Daewoong Pharmaceutical’s partner for aesthetic indications, which has also collaborated in the US and Europe, will handle local distribution and sales of Nuciva in Australia. Based on the expertise accumulated in the largest BTX markets of the US and Europe, Evolus will lead medico marketing and jointly conduct brand marketing with Daewoong Pharmaceutical in Australia.

Australia is a major market ranked within the top 10 BTX markets worldwide. As of last year, the market size is estimated to exceed 100 billion KRW. Additionally, BTX accounts for the largest share of 41% among non-surgical procedures, and the per capita procedure cost is also relatively high.

Nabota is a BTX formulation launched domestically by Daewoong Pharmaceutical in 2014. It is the only BTX in Asia approved by the US Food and Drug Administration (FDA). Manufactured based on patented high-pure technology that minimizes impurities, it is a premium high-purity toxin. The company emphasizes its high safety, rapid, and precise effects as advantages.

Seongsu Park, Vice President of Daewoong Pharmaceutical, said, “We are pleased to introduce Nuciva, which has excellent safety and quality, to Australians,” adding, “We will strive for the earliest possible launch in Australia and continue to obtain approvals and launch in multiple countries including China this year to establish Nabota as the world’s number one BTX product.”